When it is More
than a Cough

The prevalence of IPF is considered to be

14 - 42 per 100 000 worldwide1

Risk Factors of IPF

Several potential risk factors for developing IPF have been identified2

Cigarette
smoking Comorbidities Genetic
factors Environmental
exposures GERD Chronic viral
infections IPF 

COMORBIDITIES

Comorbidities may have a negative impact on patient's quality of life3

Identification and management of comorbidities may improve patient's
well-being and their quality of life4

Pulmonary
hypertension Lung
cancer Cardiovascular
and venous
thromboembolic
disease Emphysema GERD Comorbidities
associated
with IPF

be on the look out for these symptoms,
because it could be more than a cough.

References:

1. Raghu G, et al. Am J Respir Crit Care Med. 2006;174(7):810-816. 2. Raghu G, et al. Am J Respir Crit Care Med. 2011;183(6):788-824. 3. Fell C. Clin Chest Med. 2012;33(1):51-57. 4. Lee JS, et al. Curr Opin Pulm Med. 2011;17(5):348-354.

  • To report any Adverse events please use PV_local_South_Africa@boehringer-ingelheim.com
  • Should you require any further clinical information about OFEV®, please do not hesitate to contact me at renard.prinsloo@boehringer-ingelheim.com
  • S4 OFEV® 100 mg contains 100 mg nintedanib base (as esilate salt) Reg. No./Nr.: A 52/26/0153.
  • S4 OFEV® 150 mg contains 150 mg nintedanib base (as esilate salt) Reg. No./Nr.: A 52/26/0154.
  • For full prescribing information refer to the professional information approved by the Regulatory Authority.
  • Applicant details: Ingelheim Pharmaceuticals (Pty) Ltd. Suite 1, Building 4, 2nd Floor, Waterfall Corporate Campus, 74 Waterfall Drive, Midrand, 2066,
    South Africa. Tel: +27 (011) 348-2400. Cpy. Reg. No. 1966/008619/07. BI Ref. No. PC-ZA-101637. Expiry date: April 2024.